Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government’s Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021. Under the agreement, the U.S. government will receive 100 million doses of BNT162, the COVID-19 vaccine candidate jointly developed by Pfizer and BioNTech, after Pfizer successfully manufactures and obtains approval or emergency use authorization from U.S. Food and Drug Administration (FDA).

Pfizer And Biontech Announce an Agreement With U.S Government for Up To 600 Million Doses of Biontech Covid Vaccine

Pfizer Inc. (PFE)   NYSE – shares and BioNTech  rose more than 5% in pre-market trading.

Pfizer’s Market Cap is 212.628B

Forward Dividend & Yield:1.52 (4.14%)

Ex-Dividend Date: July 30, 2020

The U.S. government will pay the companies $1.95 billion upon the receipt of the first 100 million doses, following FDA authorization or approval. The U.S. government also can acquire up to an additional 500 million doses.

Americans will receive the vaccine for free consistent with U.S. government’s commitment for free access for COVID-19 vaccines.“We’ve been committed to making the impossible possible by working tirelessly to develop and produce in record time a safe and effective vaccine to help bring an end to this global health crisis,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We made the early decision to begin clinical work and large-scale manufacturing at our own risk to ensure that product would be available immediately if our clinical trials prove successful and an Emergency Use Authorization is granted. We are honored to be a part of this effort to provide Americans access to protection from this deadly virus.”

“Expanding Operation Warp Speed’s diverse portfolio by adding a vaccine from Pfizer and BioNTech increases the odds that we will have a safe, effective vaccine as soon as the end of this year,” said HHS Secretary Alex Azar. “Depending on success in clinical trials, today’s agreement will enable the delivery of approximately 100 million doses of this vaccine to the American people.” Source Pfizer

Top Institutional Holders

Holder   Shares   Date Reported   % Out       Value

Vanguard Group, Inc. (The)                   461,976,599               Mar 30, 2020           8.32%       15,078,916,191

Blackrock Inc.         424,070,197               Mar 30, 2020           7.63%       13,841,651,230

State Street Corporation                             292,621,398               Mar 30, 2020           5.27%       9,551,162,430

Capital World Investors 224,808,113               Mar 30, 2020           4.05%       7,337,736,808

Wellington Management Company, LLP 218,676,145               Mar 30, 2020           3.94%       7,137,589,372

Geode Capital Management, LLC                             89,953,885                     Mar 30, 2020           1.62%       2,936,094,806

Bank of America Corporation           86,668,244                     Mar 30, 2020           1.56%       2,828,851,484

op Mutual Fund Holders

Holder   Shares   Date Reported   % Out       Value

Vanguard Total Stock Market Index Fund                           162,364,727               Mar 30, 2020           2.92%       5,299,584,689

Vanguard 500 Index Fund                       113,925,168               Mar 30, 2020           2.05%       3,718,517,483

Washington Mutual Investors Fund                 67,478,273                     Apr 29, 2020             1.21%       2,588,466,552

Vanguard Specialized-Health Care Fund 64,114,628                     Apr 29, 2020             1.15%       2,459,437,130

SPDR S&P 500 ETF Trust 59,033,690                     May 30, 2020           1.06%       2,254,496,621

American Balanced Fund                           53,532,000                     Mar 30, 2020           0.96%       1,747,284,480

Income Fund of America Inc               50,240,000                     Apr 29, 2020             0.90%       1,927,206,400

ALBERT BOURLA, DVM, PH.D. Chairman and Chief Executive Officer, Pfizer

During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as the Pfizer’s Chief Operating Officer (COO) beginning in January 2018, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions.

Previously, from February 2016 to December 2017, Albert served as Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions for increasing patient access, demonstrating the value of Pfizer’s medicines, and ensuring broader business model innovation. Source: Pfizer  

Source Image :  Volodymyr Hryshchenko and CWEB